S. Gadgeel

523 total citations
16 papers, 262 citations indexed

About

S. Gadgeel is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, S. Gadgeel has authored 16 papers receiving a total of 262 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 8 papers in Pulmonary and Respiratory Medicine and 6 papers in Molecular Biology. Recurrent topics in S. Gadgeel's work include Lung Cancer Treatments and Mutations (8 papers), Cancer Immunotherapy and Biomarkers (5 papers) and Colorectal Cancer Treatments and Studies (2 papers). S. Gadgeel is often cited by papers focused on Lung Cancer Treatments and Mutations (8 papers), Cancer Immunotherapy and Biomarkers (5 papers) and Colorectal Cancer Treatments and Studies (2 papers). S. Gadgeel collaborates with scholars based in United States, Italy and South Korea. S. Gadgeel's co-authors include M Mabry, Sakkaraiappan Ramalingam, Gregory P. Kalemkerian, Tiffany G. Huynh, Satoshi Yoda, Elizabeth L. Lockerman, Emily Chin, Alice T. Shaw, Ibiayi Dagogo‐Jack and Mahendra Singh and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Annals of Oncology.

In The Last Decade

S. Gadgeel

16 papers receiving 259 citations

Peers

S. Gadgeel
Toby Roe United Kingdom
Justin A. Budka United States
Tomoko Funazo Japan
Heathcliff Dorado García Germany
Janani Jayanthan Australia
Shyamprasad Deraje Vasudeva United States
Yingke Zhou China
Elsie F. Wu United States
Clémentine Krucker France
Toby Roe United Kingdom
S. Gadgeel
Citations per year, relative to S. Gadgeel S. Gadgeel (= 1×) peers Toby Roe

Countries citing papers authored by S. Gadgeel

Since Specialization
Citations

This map shows the geographic impact of S. Gadgeel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Gadgeel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Gadgeel more than expected).

Fields of papers citing papers by S. Gadgeel

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. Gadgeel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Gadgeel. The network helps show where S. Gadgeel may publish in the future.

Co-authorship network of co-authors of S. Gadgeel

This figure shows the co-authorship network connecting the top 25 collaborators of S. Gadgeel. A scholar is included among the top collaborators of S. Gadgeel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S. Gadgeel. S. Gadgeel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Ramalingam, Sundar, Juanita Lopez, Morten Mau‐Sørensen, et al.. (2019). OA02.05 First-In-Human Phase 1/2 Trial of Anti-AXL Antibody–Drug Conjugate (ADC) Enapotamab Vedotin (EnaV) in Advanced NSCLC. Journal of Thoracic Oncology. 14(10). S209–S209. 12 indexed citations
2.
Riely, Gregory J., Joel W. Neal, D. Ross Camidge, et al.. (2019). P1.01-127 Antitumor Activity of the Oral EGFR/HER2 Inhibitor TAK-788 in NSCLC with EGFR Exon 20 Insertions. Journal of Thoracic Oncology. 14(10). S412–S413. 3 indexed citations
3.
Curigliano, Giuseppe, Vivek Subbiah, Justin F. Gainor, et al.. (2019). Treatment with BLU-667, a potent and selective RET inhibitor, provides rapid clearance of ctDNA in patients with RET-altered non-small cell lung cancer (NSCLC) and thyroid cancer. Annals of Oncology. 30. v790–v790. 4 indexed citations
4.
Rodríguez‐Abreu, Delvys, M.C. Garassino, Emilio Esteban, et al.. (2018). KEYNOTE-189 study of pembrolizumab (pembro) plus pemetrexed (pem) and platinum vs placebo plus pem and platinum for untreated, metastatic, nonsquamous NSCLC: Does choice of platinum affect outcomes?. Annals of Oncology. 29. ix164–ix164. 4 indexed citations
5.
Garassino, Marina Chiara, Delvys Rodríguez‐Abreu, S. Gadgeel, et al.. (2018). PD.1.01 Health-Related Quality of Life with Pembrolizumab or Placebo + Pemetrexed + Platinum in Non-Squamous NSCLC: KEYNOTE-189. Journal of Thoracic Oncology. 13(9). S155–S155. 1 indexed citations
6.
Gadgeel, S., Marcin Kowanetz, Wenbo Zou, et al.. (2017). Clinical efficacy of atezolizumab (Atezo) in PD-L1 subgroups defined by SP142 and 22C3 IHC assays in 2L+ NSCLC: Results from the randomized OAK study. Annals of Oncology. 28. v460–v461. 13 indexed citations
7.
Marinis, Filippo de, Fabrice Barlési, Achim Rittmeyer, et al.. (2017). Survival and safety of atezolizumab by best overall response (BOR) in the phase III NSCLC OAK study. Annals of Oncology. 28. v467–v467. 2 indexed citations
8.
Mok, Tony, D. Ross Camidge, S. Gadgeel, et al.. (2017). MA 07.01 Patients with ALK IHC-Positive/FISH-Negative NSCLC Benefit from ALK TKI Treatment: Response Data from the Global ALEX Trial. Journal of Thoracic Oncology. 12(11). S1826–S1826. 2 indexed citations
9.
Gainor, Justin F., Leila Dardaei, Satoshi Yoda, et al.. (2016). Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer. European Journal of Cancer. 69. S138–S138. 119 indexed citations
10.
11.
Soria, J.C., Lecia V. Sequist, Heather A. Wakelee, et al.. (2014). 10LBA Interim phase 2 results of study CO-1686-008: A phase 1/2 study of the irreversible, mutant selective, EGFR inhibitor rociletinib (CO-1686) in patients with advanced non small cell lung cancer. European Journal of Cancer. 50. 199–199. 4 indexed citations
12.
Worden, Frank, et al.. (2004). Phase II study of fenretinide in patients with small cell lung cancer (SCLC) with progression after first- or second-line chemotherapy. Journal of Clinical Oncology. 22(14_suppl). 7299–7299. 3 indexed citations
13.
Gadgeel, S., et al.. (2004). Gefitinib and celecoxib in patients with platinum refractory non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 22(14_suppl). 7094–7094. 1 indexed citations
14.
Alousi, Amin M., et al.. (2004). Phase I clinical trial of XK469 in patients with chemo-refractory solid tumors. Journal of Clinical Oncology. 22(14_suppl). 2020–2020. 1 indexed citations
15.
Kalemkerian, Gregory P., Agnieszka Woźniak, John C. Ruckdeschel, et al.. (2004). Celecoxib (CEL) and weekly docetaxel (DOC) in elderly or PS2 patients (pts) with advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 22(14_suppl). 7102–7102. 3 indexed citations
16.
Kalemkerian, Gregory P., et al.. (1995). Growth Inhibition and Induction of Apoptosis by Fenretinide in Small-Cell Lung Cancer Cell Lines. JNCI Journal of the National Cancer Institute. 87(22). 1674–1680. 88 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Toby Roe Breakdown of academic impact, for papers by Justin A. Budka Breakdown of academic impact, for papers by Tomoko Funazo Breakdown of academic impact, for papers by Heathcliff Dorado García Breakdown of academic impact, for papers by Janani Jayanthan Breakdown of academic impact, for papers by Shyamprasad Deraje Vasudeva Breakdown of academic impact, for papers by Yingke Zhou Breakdown of academic impact, for papers by Elsie F. Wu Breakdown of academic impact, for papers by Clémentine Krucker
Rankless by CCL
2026